Therapeutic potential of TDT 067 (terbinafine in Transfersome®): a carrier-based dosage form of terbinafine for onychomycosis

Bibliography

• Haneke E. Achilles foot-screening project: background, objectives and design. J Eur Acad Dermatol Venereol 1999;12(Suppl 1):S2-5; discussion S17
   PubMed Web of Science ®Google Scholar
• Elewski BE, Charif MA. Prevalence of onychomycosis in patients attending a dermatology clinic in northeastern Ohio for other conditions. Arch Dermatol 1997;133(9):1172-3
   PubMed Web of Science ®Google Scholar
• Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992;126(Suppl 39):23-7
   PubMedGoogle Scholar
• Sais G, Jucglà A, Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: a cross-sectional study. Br J Dermatol 1995;132(5):758-61
   PubMed Web of Science ®Google Scholar
• Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995;133(5):699-703
   PubMed Web of Science ®Google Scholar
• Svejgaard EL, Nilsson J. Onychomycosis in Denmark: prevalence of fungal nail infection in general practice. Mycoses 2004;47(3-4):131-5
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Steingrímsson O, Sveinsdóttir S. Prevalence of onychomycosis in Iceland: a population-based study. Acta Derm Venereol 2002;82(6):467-9
   PubMed Web of Science ®Google Scholar
• Gupta AK, Jain HC, Lynde CW, Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol 2000;43(2 Pt 1):244-8
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Hajjeh RA, Scher R, A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol 2000;43(4):641-8
   PubMed Web of Science ®Google Scholar
• Roberts DT. Oral therapeutic agents in fungal nail disease. J Am Acad Dermatol 1994;31(3 Pt 2):S78-81
   Google Scholar
• Evans EG, Sigurgeirsson B. Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group. BMJ 1999;318(7190):1031-5
   PubMed Web of Science ®Google Scholar
• Hay RJ. Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions. J Am Acad Dermatol 1993;29(1):S50-4
   PubMed Web of Science ®Google Scholar
• Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol 1999;141(Suppl 56):26-32
   PubMedGoogle Scholar
• Gupta AK. Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. J Am Acad Dermatol 2000;43(4 Suppl):S81-95
   Google Scholar
• Joseph W. Are DPMs truly treating onychomycosis. Podiatry Today. 2011. Available from: http://www.podiatrytoday.com/article/3167 [Last accessed 11 November 2011]
   Google Scholar
• Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007(3):CD001434
   PubMed Web of Science ®Google Scholar
• Elewski BE, Ghannoum MA, Mayser P, Efficacy, safety and tolerability of topical terbinafine nail solution in patients with mild to moderate toenail onychomycosis: results from three randomized studies using double-blind vehicle-controlled and open-label active controlled designs. J Eur Acad Dermatol Venereol 2011. [Epub ahead of print]
   Web of Science ®Google Scholar
• Scher RK, Tavakkol A, Sigurgeirsson B, Onychomycosis: diagnosis and definition of cure. J Am Acad Dermatol 2007;56(6):939-44
   PubMed Web of Science ®Google Scholar
• Aly R. Ecology and epidemiology of dermatophyte infections. J Am Acad Dermatol 1994;31(3 Pt 2):S21-5
   Google Scholar
• Boyko EJ, Ahroni JH, Cohen V, Prediction of diabetic foot ulcer occurrence using commonly available clinical information: the Seattle Diabetic Foot Study. Diabetes Care 2006;29:1202-7
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Sigurgeirsson B, Korting HC, Chronic dermatomycoses of the foot as risk factors for acute bacterial cellulitis of the leg: a case-control study. Dermatology 2004;209:301-7
   PubMed Web of Science ®Google Scholar
• Drake LA, Scher RK, Smith EB, Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998;38(5 Pt 1):702-4
   PubMed Web of Science ®Google Scholar
• Roseeuw D. Achilles foot screening project: preliminary results of patients screened by dermatologists. J Eur Acad Dermatol Venereol 1999;12(Suppl 1):S6-9; discussion S17
   Google Scholar
• Sigurgeirsson B, Steingrímsson O. Risk factors associated with onychomycosis. J Eur Acad Dermatol Venereol 2004;18:48-51
   PubMed Web of Science ®Google Scholar
• Tosti A, Hay R, Arenas-Guzmán R. Patients at risk of onychomycosis - risk factor identification and active prevention. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):13-16
   PubMed Web of Science ®Google Scholar
• Saunte DM, Holgersen JB, Haedersdal M, Prevalence of toe nail onychomycosis in diabetic patients. Acta Derm Venereol 2006;86:425-8
   PubMed Web of Science ®Google Scholar
• Gudnadottir G, Hilmarsdóttir I, Sigurgeirsson B. Onychomycosis in Icelandic swimmers. Acta Derm Venereol 1999;79:376-7
   PubMed Web of Science ®Google Scholar
• Hilmarsdóttir I, Haraldsson H, Sigurdardottir A, Sigurgeirsson B. Dermatophytes in a swimming pool facility: difference in dermatophyte load in men's and women's dressing rooms. Acta Derm Venereol 2005;85:267-8
   PubMed Web of Science ®Google Scholar
• Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol 2004;50(5):748-52
   PubMed Web of Science ®Google Scholar
• Kasai T. 1997 Epidemiological survey of dermatophytoses in Japan. Nippon Ishinkin Gakkai Zasshi 2001;42:11-18
   Google Scholar
• Crawford F, Young P, Godfrey C, Oral treatments for toenail onychomycosis: a systematic review. Arch Dermatol 2002;138:811-16
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Billstein S, Rantanen T, L.I.ON. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. Lamisil vs. Itraconazole in Onychomycosis. Br J Dermatol 1999;141(Suppl 56):5-14
   PubMed Web of Science ®Google Scholar
• Havu V, Heikkila H, Kuokkanen K, A double-blind, randomized study to compare the efficacy and safety of terbinafine (Lamisil) with fluconazole (Diflucan) in the treatment of onychomycosis. Br J Dermatol 2000;142:97-102
   PubMed Web of Science ®Google Scholar
• Gupta AK, Lynch LE, Kogan N, Cooper EA. The use of an intermittent terbinafine regimen for the treatment of dermatophyte toenail onychomycosis. J Eur Acad Dermatol Venereol 2009;23:256-62
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JB, Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 2002;138:353-7
   PubMed Web of Science ®Google Scholar
• Roberts DT, Taylor WD, Boyle J; British Association of Dermatologists. Guidelines for treatment of onychomycosis. Br J Dermatol 2003;148:402-10
   PubMed Web of Science ®Google Scholar
• Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Taskforce on Onychomycosis Education. Treatment options - development of consensus guidelines. J Eur Acad Dermatol Venereol 2005;19(Suppl 1):25-33
   PubMedGoogle Scholar
• Seebacher C, Brasch J, Abeck D, Onychomycosis. Mycoses. 2007;50:321-7
   Google Scholar
• de Berker D. Clinical practice. Fungal nail disease. N Engl J Med 2009;360:2108-16
   PubMed Web of Science ®Google Scholar
• Chambers WM, Millar A, Jain S, Burroughs AK. Terbinafine-induced hepatic dysfunction. Eur J Gastroenterol Hepatol 2001;13:1115-18
   PubMed Web of Science ®Google Scholar
• Tuccori M, Bresci F, Guidi B, Fatal hepatitis after long-term pulse itraconazole treatment for onychomycosis. Ann Pharmacother 2008;42(7):1112-17
   PubMed Web of Science ®Google Scholar
• Bansgaard N, Saunte DM, Folkenberg M, Zachariae C. Serious adverse events reporting on systemic terbinafine: a Danish register-based study. Acta Derm Venereol 2011;91(3):358-9
   PubMed Web of Science ®Google Scholar
• Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol 2000;43(4 Suppl):S70-80
   PubMed Web of Science ®Google Scholar
• Gupta AK; Onychomycosis Combination Therapy Study Group. Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: a randomized, evaluator-blinded study. J Drugs Dermatol 2005;4(4):481-5
   PubMedGoogle Scholar
• Baran R, Sigurgeirsson B, de Berker D, A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement. Br J Dermatol 2007;157(1):149-57
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Olafsson JH, Steinsson JT, Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years. J Eur Acad Dermatol Venereol 2010;24(8):910-15
   PubMed Web of Science ®Google Scholar
• Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol 2003;149(Suppl 65):5-9
   PubMed Web of Science ®Google Scholar
• Murdan S. Enhancing the nail permeability of topically applied drugs. Expert Opin Drug Deliv 2008;5:1267-82
   PubMed Web of Science ®Google Scholar
• Gupta AK, Malkin KF. Ciclopirox nail lacquer and podiatric practice. J Am Podiatr Med Assoc 2000;90(10):502-7
   PubMed Web of Science ®Google Scholar
• Amichai B, Nitzan B, Mosckovitz R, Shemer A. Iontophoretic delivery of terbinafine in onychomycosis: a preliminary study. Br J Dermatol 2010;162(1):46-50
   PubMed Web of Science ®Google Scholar
• Nair AB, Chakraborty B, Murthy SN. Effect of polyethylene glycols on the trans-ungual delivery of terbinafine. Curr Drug Deliv 2010;7(5):407-14
   PubMedGoogle Scholar
• Ghannoum MA, Long L, Pfister WR. Determination of the efficacy of terbinafine hydrochloride nail solution in the topical treatment of dermatophytosis in a guinea pig model. Mycoses 2009;52(1):35-43
   PubMed Web of Science ®Google Scholar
• Hui X, Baker SJ, Wester RC, In vitro penetration of a novel oxaborole antifungal (AN2690) into the human nail plate. J Pharm Sci 2007;96(10):2622-31
   PubMed Web of Science ®Google Scholar
• Beutner K, Toledo-Bahena M, Barbosa-Alanis H, Interim results of a multicenter study to evaluate the safety and efficacy of topically applied AN2690 5.0% and 7.5% solutions for the treatment of onychomycosis of the great toenail [abstract no. P1802]. American Academy of Dermatology Annual Meeting; 2007
   Google Scholar
• Pannu J, McCarthy A, Martin A, NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob Agents Chemother 2009;53(8):3273-9
   PubMed Web of Science ®Google Scholar
• Ijzerman M, Baker J Jr, Flack M, Robinson P. Efficacy of topical nanoemulsion (NB-002) for the treatment of distal subungual onychomycosis: a randomized, double-blind, vehicle-controlled trial [abstract no. P2108]. American Academy of Dermatology Annual Meeting; 2010
   Google Scholar
• Cevc G. Drug delivery across the skin. Expert Opin Investig Drugs 1997;6:1887-937
   PubMedGoogle Scholar
• Cevc G, Mazgareanu S, Rother M. Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels. Int J Pharm 2008;360(1-2):29-39
   PubMedGoogle Scholar
• Ghannoum M, Isham N, Henry W, Yurdakul S. Evaluation of the broad-spectrum antimicrobial activity of TDT 067 (terbinafine in Transfersome®) against dermatophytes, yeasts, filamentous fungi, and bacteria [abstract no. 31105]. Infectious Diseases Society of America Annual Meeting; 2011
   Google Scholar
• Ghannoum M, Isham N, Henry W, Yurdakul S. Evaluation of the antifungal activity of TDT 067 (terbinafine in Transfersome®) in combination with antifungals used in the treatment of systemic fungal infections [abstract no. 31117]. Infectious Diseases Society of America Annual Meeting; 2011
   Google Scholar
• Fesq H, Lehmann J, Kontny A, Improved risk-benefit ratio for topical triamcinolone acetonide in transfersome in comparison with equipotent cream and ointment: a randomized controlled trial. Br J Dermatol 2003;149(3):611-19
   PubMed Web of Science ®Google Scholar
• Benson HA. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv 2006;3:727-37
   PubMed Web of Science ®Google Scholar
• Kneer W, Rother I, Rother M, Seidel E; IDEA-033-III-01 Study Group. A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf 2009;4(1):5-10
   PubMedGoogle Scholar
• Rother M, Lavins BJ, Kneer W, Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007;66(9):1178-83
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Isham N, Herbert J, Activity of TDT 067 (terbinafine in Transfersomes) against agents of onychomycosis, as determined by minimum inhibitory and fungicidal concentration. J Clin Microbiol 2011;49:1716-20
   PubMed Web of Science ®Google Scholar
• Ghannoum MA, Welshenbaugh A, Imamura Y, Comparison of the in vitro activity of terbinafine and lanoconazole against dermatophytes. Mycoses 2010;53(4):311-13
   PubMed Web of Science ®Google Scholar
• Iorizzo M, Piraccini BM, Tosti A. New fungal nail infections. Curr Opin Infect Dis 2007;20(2):142-5
   PubMed Web of Science ®Google Scholar
• Gupta AK, Ryder JE, Baran R, Summerbell RC. Non-dermatophyte onychomycosis. Dermatol Clin 2003;21(2):257-68
   PubMed Web of Science ®Google Scholar
• Dominicus R, Weidner C, Tate H, Kroon H-A. Open-label study of the efficacy and safety of topical treatment with TDT 067 (terbinafine in Transfersome®) in patients with onychomycosis. Br J Dermatol 2012;166:1360-2
   PubMed Web of Science ®Google Scholar
• Zaias N, Drachmann D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol 1983;9:912-19
   PubMed Web of Science ®Google Scholar
• Yu H-J, Kwon H-M, Oh D-H, Kim JS. Is slow nail growth a risk factor for onychomycosis? Clin Exp Dermatol 2004;29:415-18
   PubMed Web of Science ®Google Scholar
• Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992;17(Suppl 1):41-3
   PubMed Web of Science ®Google Scholar
• Goodfield MJ, Andrew L, Evans EG. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ 1992;304:1151-4
   PubMed Web of Science ®Google Scholar
• van der Schroeff JG, Cirkel PK, Crijns MB, A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol 1992;126(Suppl 39):36-9
   PubMedGoogle Scholar
• Bräutigam M. Terbinafine versus itraconazole: a controlled clinical comparison in onychomycosis of the toenails. J Am Acad Dermatol 1998;38:S53-6
   PubMed Web of Science ®Google Scholar
• Ghannoum M, Isham N, Henry W, Evaluation of the morphological effects of TDT 067 (terbinafine in Transfersome®) and conventional terbinafine on dermatophyte hyphae in vitro and in vivo. Antimicrob Agents Chemother 2012;56:2530-4
   PubMed Web of Science ®Google Scholar
• Tschen EH, Jones TM, Kroon H-A. Safety and pharmacokinetics of TDT 067 under conditions of maximal use in onychomycosis of the toenails [abstract no. CARL8-0130]. European Academy of Dermatology and Venereology Spring Symposium; 2011
   Google Scholar
• Ghannoum M, Isham N, Henry W, Yurdakul S. Morphological changes in dermatophyte hyphae within nail samples obtained from onychomycosis patients treated with TDT 067 (terbinafine in Transfersome) [abstract no. PO28]. 2011e; 5th Trends in Medical Mycology/European Confederation of Medical Mycology Biannual Meeting; 2011
   Google Scholar
• Schatz F, Brautigam M, Dobrowolski E, Nail incorporation kinetics of terbinafine in onychomycosis patients. Clin Exp Dermatol 1995;20(5):377-83
   PubMed Web of Science ®Google Scholar
• Faergemann J, Zehender H, Boukhabza A, A double-blind comparison of levels of terbinafine and itraconazole in plasma, skin, sebum, hair and nails during and after oral medication. Acta Derm Venereol 1997;77(1):74-6
   PubMed Web of Science ®Google Scholar